MDxHealth S.A.

NASDAQ:MDXH

Medical - Diagnostics & Research

Healthcare
$0.60 -4.45%

-$0.03 today

Market cap
$57.59M
Beta
0.38
P/E (TTM)
-1.0
EPS (TTM)
-$0.58
52W Low $0.40High $5.33

Volume 0.65M

Average 4.27M

MDXH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

MDxHealth S.A.NASDAQ: MDXH

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $605K fell 55.5% year over year. Over 3 fiscal years it compounded at +36.6% a year.

Context

  • Stock-based compensation amounted to 2.0% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$605K— QoQ
Last fiscal yearDec 2025
$2.21M+28.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.5%——
1 year+28.2%——
3-year CAGR+36.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.21M USD
Year-over-year change
+28.2%
4-year CAGR
+16.0%

Stock-Based Compensation vs competitors

How MDXH compares with its peers on the latest reported figures

  • MDXH's FY2025 stock-based compensation of $2.21M is the 9th largest of the 11 companies compared; the peer median is $7.25M.
  • Its year-over-year change of +28.2% is the 4th highest of 10, against a peer median of -7.7%.
  • Stock-based compensation amounts to 2.0% of revenue for MDXH, versus a peer median of 6.1%.
MDXH Competitors Peer median
Stock-Based Compensation for MDXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M -2.1%-6.3%144.0%
ZURAZura Bio LimitedLTM Mar 2026$11.32M -37.2%+233.0%—
QTRXQuanterix CorporationLTM Mar 2026$9.79M +79.2%+10.3%6.8%
STXSStereotaxis, Inc.LTM Mar 2026$9.43M -7.7%-2.3%30.2%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$5.08M +64.3%-10.8%7.1%
XGNExagen Inc.LTM Mar 2026$2.4M +47.3%-22.9%3.5%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$2.38M -344.3%—5.4%
MDXHMDxHealth S.A.FY2025$2.21M +28.2%+36.6%2.0%
SIShoulder Innovations, Inc.LTM Mar 2026$1.6M ——3.0%
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding MDXH) $7.25M-7.7%-2.3%6.1%

Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.84M)(37.9M)(27.33M)(24.72M)(14.41M)
Depreciation & Amortization3.04M4.91M6.86M8.04M9.21M
Deferred Income Tax00000
Stock-Based Compensation1.22M867K665K1.73M2.21M
Change in Working Capital360K(1.57M)(2.12M)(3.86M)939K
Accounts Receivables(1.38M)(5.12M)(1.68M)(3.23M)2.32M
Inventory413K(416K)(452K)(1.09M)(1.93M)
Accounts Payables0000550K
Other Working Capital1.33M3.97M20K458K0
Other Non-Cash Items(325K)(429K)421K286K(8.37M)
Operating Cash Flow(22.55M)(34.12M)(21.5M)(18.53M)(10.42M)
Capital Expenditures(896K)(4.16M)(5.02M)(2.16M)(1.16M)
Acquisitions (Net)0(25M)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities11K(1.25M)(1.18M)(448K)(18.9M)
Investing Cash Flow(885K)(29.04M)(3.93M)(1.64M)(20.06M)
Debt Repayment(1.06M)22.13M(3.27M)11.59M21.6M
Common Stock Issued68.57M039.6M40.74M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.01M)(1.41M)(4.05M)(7.73M)(8.91M)
Financing Cash Flow66.5M20.72M32.28M44.6M12.7M
Effect of Forex Changes(520K)(555K)25K(14K)16K
Net Change in Cash42.55M(43M)6.88M24.42M(17.77M)
Free Cash Flow(23.44M)(38.28M)(26.52M)(20.69M)(11.57M)

MDxHealth S.A.

NASDAQ:MDXH

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.